WO2001023389A3 - Certain alkylene diamine-substituted heterocycles - Google Patents

Certain alkylene diamine-substituted heterocycles Download PDF

Info

Publication number
WO2001023389A3
WO2001023389A3 PCT/US2000/026886 US0026886W WO0123389A3 WO 2001023389 A3 WO2001023389 A3 WO 2001023389A3 US 0026886 W US0026886 W US 0026886W WO 0123389 A3 WO0123389 A3 WO 0123389A3
Authority
WO
WIPO (PCT)
Prior art keywords
present
alkylene diamine
substituted heterocycles
tri
mono
Prior art date
Application number
PCT/US2000/026886
Other languages
French (fr)
Other versions
WO2001023389A2 (en
Inventor
Raymond F Horvath
Jennifer Tran
Lombaert Stephane De
Kevin Julian Hodgetts
Philip A Carpino
David A Griffith
Original Assignee
Neurogen Corp
Pfizer
Raymond F Horvath
Jennifer Tran
Lombaert Stephane De
Kevin Julian Hodgetts
Philip A Carpino
David A Griffith
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP00967133A priority Critical patent/EP1224187B1/en
Priority to EA200200424A priority patent/EA200200424A1/en
Priority to PL00354784A priority patent/PL354784A1/en
Priority to AU77380/00A priority patent/AU7738000A/en
Application filed by Neurogen Corp, Pfizer, Raymond F Horvath, Jennifer Tran, Lombaert Stephane De, Kevin Julian Hodgetts, Philip A Carpino, David A Griffith filed Critical Neurogen Corp
Priority to JP2001526541A priority patent/JP2003510327A/en
Priority to KR1020027004150A priority patent/KR20020043223A/en
Priority to NZ517575A priority patent/NZ517575A/en
Priority to IL14890300A priority patent/IL148903A0/en
Priority to DE60026155T priority patent/DE60026155T2/en
Priority to CA002379640A priority patent/CA2379640C/en
Priority to HU0202636A priority patent/HUP0202636A3/en
Publication of WO2001023389A2 publication Critical patent/WO2001023389A2/en
Priority to BG106508A priority patent/BG106508A/en
Priority to NO20021358A priority patent/NO20021358L/en
Publication of WO2001023389A3 publication Critical patent/WO2001023389A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/5755—Neuropeptide Y
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor

Abstract

The present invention also provides a general method to whereby mono-, bi-, or tri-cyclic heterocycles may be modified to obtain potent antagonists at the NPY1 receptor. The present invention provides novel, potent, non-peptidic antagonists of NPY receptors, particularly, the NPY1 receptors, designed from a selection of mono-, bi-, or tri-cyclic heterocyclic cores. This invention relates to novel compounds, compositions, and methods for the treatment of physiological disorders associated with an excess of neuropeptide Y. The novel compounds encompassed by the present invention are those of the formula (I-XV).
PCT/US2000/026886 1999-09-30 2000-09-29 Certain alkylene diamine-substituted heterocycles WO2001023389A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
KR1020027004150A KR20020043223A (en) 1999-09-30 2000-09-29 Certain alkylene diamine-substituted heterocycles
PL00354784A PL354784A1 (en) 1999-09-30 2000-09-29 Certain alkylene diamine-substituted heterocycles
AU77380/00A AU7738000A (en) 1999-09-30 2000-09-29 Certain alkylene diamine-substituted heterocycles
IL14890300A IL148903A0 (en) 1999-09-30 2000-09-29 Certain alkylene diamine-substituted heterocycles
JP2001526541A JP2003510327A (en) 1999-09-30 2000-09-29 Heterocycle substituted with specific alkylenediamine
EA200200424A EA200200424A1 (en) 1999-09-30 2000-09-29 Some heterocycles substituted by alkylene diamin
NZ517575A NZ517575A (en) 1999-09-30 2000-09-29 Certain alkylene diamine-substituted heterocycles
EP00967133A EP1224187B1 (en) 1999-09-30 2000-09-29 Certain alkylene diamine-substituted heterocycles
DE60026155T DE60026155T2 (en) 1999-09-30 2000-09-29 SOME ALKYLENDIAMINE-SUBSTITUTED HETEROCYCLES
CA002379640A CA2379640C (en) 1999-09-30 2000-09-29 Certain alkylene diamine-substituted heterocycles
HU0202636A HUP0202636A3 (en) 1999-09-30 2000-09-29 Certain alkylene diamine-substituted heterocycles
BG106508A BG106508A (en) 1999-09-30 2002-03-11 Alkylene diamine-substituted heterocycles
NO20021358A NO20021358L (en) 1999-09-30 2002-03-19 Alkylenediamine-substituted heterocycles

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15687099P 1999-09-30 1999-09-30
US60/156,870 1999-09-30

Publications (2)

Publication Number Publication Date
WO2001023389A2 WO2001023389A2 (en) 2001-04-05
WO2001023389A3 true WO2001023389A3 (en) 2002-05-10

Family

ID=22561438

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/026886 WO2001023389A2 (en) 1999-09-30 2000-09-29 Certain alkylene diamine-substituted heterocycles

Country Status (21)

Country Link
US (3) US6506762B1 (en)
EP (1) EP1224187B1 (en)
JP (2) JP2003510327A (en)
KR (1) KR20020043223A (en)
CN (1) CN1377356A (en)
AT (1) ATE318267T1 (en)
AU (1) AU7738000A (en)
BG (1) BG106508A (en)
CA (1) CA2379640C (en)
CZ (1) CZ20021086A3 (en)
DE (1) DE60026155T2 (en)
EA (1) EA200200424A1 (en)
ES (1) ES2258476T3 (en)
HU (1) HUP0202636A3 (en)
IL (1) IL148903A0 (en)
NO (1) NO20021358L (en)
NZ (1) NZ517575A (en)
OA (1) OA12050A (en)
PL (1) PL354784A1 (en)
WO (1) WO2001023389A2 (en)
ZA (1) ZA200202518B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8835430B2 (en) 2002-02-01 2014-09-16 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US9266912B2 (en) 2005-01-19 2016-02-23 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses

Families Citing this family (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6340683B1 (en) 1999-04-22 2002-01-22 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (triazines)
US6989379B1 (en) 1999-04-22 2006-01-24 H. Lundbick A/S Selective NPY (Y5) antagonists
ES2284491T3 (en) 1999-04-22 2007-11-16 H. Lundbeck A/S NPY SELECTIVE ANTAGONISTS (Y5).
US7273880B2 (en) 1999-06-30 2007-09-25 H. Lunbeck A/S Selective NPY (Y5) antagonists
CZ20021086A3 (en) * 1999-09-30 2002-10-16 Neurogen Corporation Alkylenediamine substituted heterocycles
IL148905A0 (en) * 1999-09-30 2002-09-12 Neurogen Corp Pfizer Inc Certain alkylene diamine-substituted pyrazolo{1,5,-a}-1,5-pyrimidines and pyrazolo{1,5,-a}-1,3,5-triazines
US20010031474A1 (en) * 2000-01-28 2001-10-18 Neurogen Corporation Chimeric neuropeptide Y receptors
EA006153B1 (en) * 2000-06-26 2005-10-27 Пфайзер Продактс Инк. PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS
US20050033048A1 (en) * 2000-12-12 2005-02-10 Rajagopal Bakthavatchalam Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines
CN100343258C (en) * 2001-04-30 2007-10-17 美国拜尔公司 Novel 4-amino-5,6-substituted thiopheno 2,3-d]pyrimidines
US7279474B2 (en) 2001-04-30 2007-10-09 Glaxo Group Limited Substituted pyrrolo[2,3-d]pyrimidines as antagonists of the corticotropin releasing factor (CRF)
US20070122353A1 (en) * 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US7498019B2 (en) 2001-05-24 2009-03-03 Alexza Pharmaceuticals, Inc. Delivery of compounds for the treatment of headache through an inhalation route
US6805853B2 (en) * 2001-11-09 2004-10-19 Alexza Molecular Delivery Corporation Delivery of diazepam through an inhalation route
US7090830B2 (en) * 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US6759029B2 (en) * 2001-05-24 2004-07-06 Alexza Molecular Delivery Corporation Delivery of rizatriptan and zolmitriptan through an inhalation route
CA2447519C (en) * 2001-05-24 2008-09-16 Alexza Molecular Delivery Corporation Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
EP1392262A1 (en) * 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US20030051728A1 (en) * 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
US7458374B2 (en) * 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
GB0117396D0 (en) 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
US7323469B2 (en) 2001-08-07 2008-01-29 Novartis Ag 7H-pyrrolo[2,3-d]pyrimidine derivatives
US6787558B2 (en) 2001-09-28 2004-09-07 Hoffmann-La Roche Inc. Quinoline derivatives
CA2403307A1 (en) 2001-10-23 2003-04-23 Neurogen Corporation Substituted 2-cyclohexyl-4-phenyl-1h-imidazole derivatives
EP1446102A1 (en) * 2001-11-21 2004-08-18 Alexza Molecular Delivery Corporation Delivery of caffeine through an inhalation route
WO2003094900A1 (en) 2002-05-13 2003-11-20 Alexza Molecular Delivery Corporation Delivery of drug amines through an inhalation route
US20060193788A1 (en) * 2002-11-26 2006-08-31 Hale Ron L Acute treatment of headache with phenothiazine antipsychotics
TW200410688A (en) * 2002-06-26 2004-07-01 Ono Pharmaceutical Co Therapeutics for diseases from vasoconstriction or vasodilatation
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
JP2005535648A (en) 2002-07-05 2005-11-24 エフ．ホフマン−ラ　ロシュ　アーゲー Quinazoline derivatives
IL166241A (en) 2002-07-29 2011-12-29 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds for use in the treatment of autoimmune diseases
EP1539722A1 (en) 2002-08-07 2005-06-15 F. Hoffmann-La Roche Ag Thiazole derivatives
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
AU2003295823B2 (en) * 2002-11-26 2009-11-05 Alexza Pharmaceuticals, Inc. Treatment of headache with antipsychotics delivered by inhalation
JP2006514934A (en) * 2002-11-26 2006-05-18 アレックザ ファーマシューティカルズ， インコーポレイテッド Use of loxapine or amoxapine for the manufacture of drugs for the treatment of pain
US7550133B2 (en) * 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
US20040105818A1 (en) * 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7913688B2 (en) * 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
US20040192583A1 (en) * 2002-12-19 2004-09-30 Satyanarayana Medicherla Treatment of obesity and associated conditions with TGF-beta inhibitors
EA011009B1 (en) 2003-01-14 2008-12-30 Арена Фармасьютикалз Инк. 1,2,3-substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
EA008596B1 (en) 2003-04-29 2007-06-29 Пфайзер Инк. 5,7-DIAMINOPYRAZOLO[4,3-d]PYRIMIDINES USEFUL IN THE TREATMENT OF HYPERTENSION
JP2007516404A (en) 2003-05-21 2007-06-21 アレックザ ファーマシューティカルズ， インコーポレイテッド Optically or electrically ignited built-in heating unit and drug supply unit using the same
WO2004110454A1 (en) * 2003-06-13 2004-12-23 Ishihara Sangyo Kaisha, Ltd. COMPOSITION FOR TREATMENT FOR OR PREVENTION OF DISEASE NECESSITATING ADMINISTRATION OF ADENOSINE A2a RECEPTOR AGONIST
US7132426B2 (en) * 2003-07-14 2006-11-07 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
JP4886511B2 (en) 2003-07-30 2012-02-29 ライジェル ファーマシューティカルズ， インコーポレイテッド Method for treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
JP2007502776A (en) * 2003-08-15 2007-02-15 アイアールエム・リミテッド・ライアビリティ・カンパニー 6-Substituted anilinopurines as RTK inhibitors
ES2279446T3 (en) 2003-08-15 2007-08-16 MERCK & CO., INC. NMDA / NR2B ANTAGONISTS OF 4-CYCLALKYLAMINOPIRAZOLO PYRIMIDINE.
WO2005019222A1 (en) * 2003-08-15 2005-03-03 Merck & Co., Inc. 4-cycloalkylaminopyrazolo pyrimidine nmda/nr2b antagonists
AU2004274309B2 (en) 2003-09-22 2010-04-08 Msd K.K. Novel piperidine derivative
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
BRPI0418368A (en) * 2004-01-06 2007-05-15 Janssen Pharmaceutica Nv (3-oxo-3,4-dihydro-quinoxalin2-ylamino) -benzamide derivatives and related compounds as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
CA2559629A1 (en) 2004-03-16 2005-09-29 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compound, and its use as a pde4 inhibitor
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
ATE417849T1 (en) 2004-04-07 2009-01-15 Pfizer PYRAZOLOA4,3-DÜPYRIMIDINE
US7540286B2 (en) * 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
US20100006092A1 (en) * 2004-08-12 2010-01-14 Alexza Pharmaceuticals, Inc. Aerosol Drug Delivery Device Incorporating Percussively Activated Heat Packages
EP1781360A1 (en) * 2004-08-12 2007-05-09 Alexza Pharmaceuticals, Inc. Aerosol drug delivery device incorporating percussively activated heat packages
ES2326827T3 (en) * 2004-10-19 2009-10-20 Smithkline Beecham (Cork) Limited ANATAGONISTS OF THE RECEIVER OF CRF AND RELATED METHODS.
EP2286838A3 (en) 2004-11-01 2013-09-04 Amylin Pharmaceuticals, LLC Treatment of obesity and related disorders
ES2380550T3 (en) 2004-11-24 2012-05-16 Rigel Pharmaceuticals, Inc. Spiro-2,4-pyrimidinediamine compounds and their uses
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
CA2609388C (en) 2005-05-30 2013-08-06 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivative
CA2615946A1 (en) * 2005-07-22 2007-02-01 Sunesis Pharmaceuticals, Inc. Pyrazolo pyrimidines useful as aurora kinase inhibitors
AU2006277253A1 (en) 2005-08-10 2007-02-15 Msd K.K. Pyridone compound
EP2330125A3 (en) 2005-08-11 2012-12-12 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
AU2006279680B2 (en) 2005-08-11 2012-12-06 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
EP1921065B1 (en) 2005-08-24 2010-10-20 Banyu Pharmaceutical Co., Ltd. Phenylpyridone derivative
EP1939194A4 (en) 2005-09-07 2010-12-08 Banyu Pharma Co Ltd Bicyclic aromatic substituted pyridone derivative
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
EP1940842B1 (en) 2005-09-29 2012-05-30 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
JP2009512715A (en) 2005-10-21 2009-03-26 ノバルティス アクチエンゲゼルシャフト Combination of renin inhibitor and anti-dyslipidemic agent and / or anti-obesity agent
EP1944301A4 (en) 2005-10-27 2012-01-04 Msd Kk Novel benzoxathiin derivative
RU2428423C2 (en) 2005-11-10 2011-09-10 Баниу Фармасьютикал Ко., Лтд. Aza-substituted spiro-derivatives
JP5489333B2 (en) 2006-09-22 2014-05-14 メルク・シャープ・アンド・ドーム・コーポレーション Methods of treatment using fatty acid synthesis inhibitors
AU2007301126A1 (en) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
WO2008112661A2 (en) 2007-03-09 2008-09-18 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
WO2008120653A1 (en) 2007-04-02 2008-10-09 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
US20160331729A9 (en) * 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
RU2492858C2 (en) * 2007-04-11 2013-09-20 Омерос Корпорейшн Compositions and methods of preventing and treating addictions
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2527360B1 (en) 2007-06-04 2015-10-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2009034411A1 (en) * 2007-09-12 2009-03-19 Centre National De La Recherche Scientifique Perharidines as cdk inhibitors
AU2009220605A1 (en) 2008-03-06 2009-09-11 Msd K.K. Alkylaminopyridine derivative
AU2009229860A1 (en) 2008-03-28 2009-10-01 Msd K.K. Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor
WO2009132980A1 (en) 2008-04-29 2009-11-05 F. Hoffmann-La Roche Ag Pyrimidinyl pyridone inhibitors of jnk.
ES2627848T3 (en) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JPWO2009154132A1 (en) 2008-06-19 2011-12-01 Ｍｓｄ株式会社 Spirodiamine-diarylketoxime derivatives
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2319841A1 (en) 2008-07-30 2011-05-11 Msd K.K. (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
WO2010020905A1 (en) 2008-08-20 2010-02-25 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine compounds
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
KR101320245B1 (en) 2008-10-30 2013-10-30 머크 샤프 앤드 돔 코포레이션 Isonicotinamide orexin receptor antagonists
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010075069A1 (en) 2008-12-16 2010-07-01 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
EP2379547A1 (en) 2008-12-16 2011-10-26 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
BR112012008330B1 (en) * 2009-09-03 2022-03-22 Bristol-Myers Squibb Company Quinazoline compounds, their pharmaceutical compositions and their uses
WO2011089400A1 (en) 2010-01-22 2011-07-28 Centro Nacional De Investigaciones Oncológicas (Cnio) Inhibitors of pi3 kinase
SG182610A1 (en) 2010-01-27 2012-08-30 Arena Pharm Inc Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
CA2786314A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EA201390421A1 (en) 2010-09-22 2013-09-30 Арена Фармасьютикалз, Инк. GPR119 RECEPTOR MODULATORS AND TREATMENT OF RELATED DISORDERS
CA2826649C (en) 2011-02-25 2016-07-26 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
CN102219791A (en) * 2011-04-08 2011-10-19 天津希恩思生化科技有限公司 Color biotin used for large biological molecule marking, as well as applications in preparing large biological molecule marking reagent
AU2012262021B2 (en) * 2011-06-01 2016-07-28 Janus Biotherapeutics, Inc. Novel immune system modulators
AR088352A1 (en) 2011-10-19 2014-05-28 Merck Sharp & Dohme ANTAGONISTS OF THE RECEIVER OF 2-PIRIDILOXI-4-NITRILE OREXINE
MX355088B (en) 2011-11-23 2018-04-04 Cancer Research Tech Ltd Thienopyrimidine inhibitors of atypical protein kinase c.
AU2012356083B2 (en) 2011-12-22 2015-01-22 Novartis Ag Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
US20140045746A1 (en) 2012-08-02 2014-02-13 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CA2900779C (en) 2013-02-11 2021-10-26 The Regents Of The University Of California Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
EP2958562A4 (en) 2013-02-22 2016-08-10 Merck Sharp & Dohme Antidiabetic bicyclic compounds
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
JP2016514671A (en) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド Guanylate cyclase agonists and uses thereof
JP2016514670A (en) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド Guanylate cyclase receptor agonists in combination with other drugs
BR112015030326A2 (en) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc ULTRAPURE GUANYLATE CYCLASE C AGONISTS, METHOD OF MANUFACTURING AND USING THEM
KR101666700B1 (en) * 2013-07-15 2016-10-17 주식회사 엘지화학 Polymer and organic solar cell comprising the same
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
BR112017003745A2 (en) 2014-08-29 2017-12-05 Tes Pharma S R L alpha-amino-beta-carboximuconic acid semialdehyde decarboxylase inhibitors
GB201416628D0 (en) * 2014-09-19 2014-11-05 Johnson Matthey Plc Complexes and methods for their preparation
UA126268C2 (en) 2015-01-06 2022-09-14 Арена Фармасьютікалз, Інк. Methods of treating conditions related to the s1p1 receptor
PL3310760T3 (en) 2015-06-22 2023-03-06 Arena Pharmaceuticals, Inc. Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in s1p1 receptor-associated disorders
CN109952292A (en) 2016-10-14 2019-06-28 Tes制药有限责任公司 Pantonine-carboxyl muconic acid semialdehyde removes the inhibitor of carboxylic acid
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
JP2020507611A (en) 2017-02-16 2020-03-12 アリーナ ファーマシューティカルズ， インコーポレイテッド Compounds and methods for the treatment of primary biliary cholangitis
US11414419B2 (en) 2017-06-21 2022-08-16 Mitokinin, Inc. Substituted purines for the treatment of neurodegenerative and mitochondrial diseases
US11427578B1 (en) 2017-07-18 2022-08-30 Bayer Pharma Aktiengesellschaft Substituted pyrrolopyridine-derivatives
AR117398A1 (en) 2018-03-12 2021-08-04 Abbvie Inc INHIBITORS OF SIGNALING MEDIATED BY TYROSINE KINASE 2
BR112021009589A2 (en) 2018-11-20 2021-08-17 Tes Pharma S.R.L. alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase inhibitors
US20220047603A1 (en) 2018-12-11 2022-02-17 Bayer Aktiengesellschaft Substituted pyrrolopyridine-derivatives
WO2020167706A1 (en) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
EP4010314B1 (en) 2019-08-08 2024-02-28 Merck Sharp & Dohme LLC Heteroaryl pyrrolidine and piperidine orexin receptor agonists
EP3800188A1 (en) 2019-10-02 2021-04-07 Bayer AG Substituted pyrazolopyrimidines as irak4 inhibitors
WO2021249913A1 (en) 2020-06-09 2021-12-16 Bayer Aktiengesellschaft 2'-(quinolin-3-yl)-5',6'-dihydrospiro[azetidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate derivatives and related compounds as map4k1 (hpk1) inhibitors for the treatment of cancer
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
WO2022006456A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic pyridone compounds as jak2 v617f inhibitors
TW202216713A (en) 2020-07-02 2022-05-01 美商英塞特公司 Tricyclic urea compounds as jak2 v617f inhibitors
BR112023002957A2 (en) 2020-08-18 2023-04-04 Merck Sharp & Dohme Llc COMPOUND, PHARMACEUTICAL COMPOSITION, AND, METHODS FOR TREATING NARCOLEPSY AND FOR TREATING HYPERSONIA IN A MAMMAL SUBJECT
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
EP4288437A1 (en) 2021-02-05 2023-12-13 Bayer Aktiengesellschaft Map4k1 inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003510A1 (en) * 1996-07-24 1998-01-29 Du Pont Pharmaceuticals Company Azolo triazines and pyrimidines
WO1999038868A1 (en) * 1998-01-28 1999-08-05 Du Pont Pharmaceuticals Company Azolo triazines and pyrimidines
WO1999040091A1 (en) * 1998-02-06 1999-08-12 Amgen Inc. Bicyclic pyridine and pyrimidine derivatives as neuropeptide y receptor antagonists

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2437683A (en) * 1948-03-16 Pyrimedine compounds and method of
US2465568A (en) * 1949-03-29 Pyrimidine compounds
GB587550A (en) * 1944-09-25 1947-04-29 Francis Henry Swinden Curd New pyrimidine compounds
EP0239191A3 (en) 1986-01-30 1988-07-20 Beecham Group Plc Pyrazolo[4,3-b]pyridine derivatives, process for their preparation and pharmaceutical compositions containing them
US5273608A (en) 1990-11-29 1993-12-28 United Solar Systems Corporation Method of encapsulating a photovoltaic device
KR19990067704A (en) * 1992-12-17 1999-08-25 디. 제이. 우드, 스피겔 알렌 제이 Pharmaceutical composition containing pyrrolopyrimidine as an adrenal cortical stimulating hormone free factor antagonist
TW444018B (en) 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
US5664057A (en) 1993-07-07 1997-09-02 Picturetel Corporation Fixed bit rate speech encoder/decoder
JP3398152B2 (en) * 1993-10-12 2003-04-21 ブリストル‐マイヤーズ・スクイブ・ファーマ・カンパニー 1N-alkyl-N-arylpyrimidineamine and derivatives thereof
TW530047B (en) 1994-06-08 2003-05-01 Pfizer Corticotropin releasing factor antagonists
PL181895B1 (en) 1994-06-16 2001-10-31 Pfizer Pyrazole and pyrrole pyridines
US6562862B1 (en) 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
EP0729758A3 (en) 1995-03-02 1997-10-29 Pfizer Pyrazolopyrimidines and pyrrolopyrimidines for treatment of neuronal and other disorders
ATE182148T1 (en) 1995-05-12 1999-07-15 Neurogen Corp NEW DEAZAPURINE DERIVATIVES; A NEW CLASS OF CRF1-SPECIFIC LIGANDS
US6403599B1 (en) * 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
US5955613A (en) 1995-10-13 1999-09-21 Neurogen Corporation Certain pyrrolopyridine derivatives; novel CRF1 specific ligands
KR19990045744A (en) 1995-10-17 1999-06-25 뉴로크린 바이오사이언시즈 인코퍼레이티드 Amino substituted pyrimidines and triazines
ATE243697T1 (en) 1995-12-08 2003-07-15 Pfizer SUBSTITUTED HETEROCYCLIC DERIVATIVES AS CRF ANTAGONISTS
PT882051E (en) * 1996-02-07 2002-04-29 Janssen Pharmaceutica Nv THYOPHENOPYRIMIDINES
WO1997033580A1 (en) 1996-03-11 1997-09-18 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Maintaining kidney function during surgery or trauma
US6326368B1 (en) * 1996-03-27 2001-12-04 Dupont Pharmaceuticals Company Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
ZA973884B (en) 1996-05-23 1998-11-06 Du Pont Merck Pharma Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
TW477787B (en) * 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
HUP9903965A3 (en) 1996-08-28 2002-02-28 Pfizer Substituted 6,5-hetero-bicyclic derivatives
AU7890598A (en) 1996-12-27 1998-07-31 Yoshitomi Pharmaceutical Industries, Ltd. Fused pyrimidine compounds and medicinal use thereof
WO1998035967A2 (en) 1997-02-18 1998-08-20 Neurocrine Biosciences, Inc. Biazacyclic crf antagonists
PL335887A1 (en) 1997-03-21 2000-05-22 Du Pont Pharm Co Method of obtaining arylaminotriazole pyridines
AU733604B2 (en) 1997-03-26 2001-05-17 Taisho Pharmaceutical Co., Ltd. 4-tetrahydropyridylpyrimidine derivative
ES2207834T3 (en) 1997-04-22 2004-06-01 Janssen Pharmaceutica N.V. QUINO- AND ANTAGONIST QUINAZOLINS OF CRF.
AU751710B2 (en) 1997-04-22 2002-08-22 Neurocrine Biosciences Inc. CRF antagonistic thiophenopyridines
NL1010018C2 (en) 1997-09-09 1999-03-10 Duphar Int Res Quinoline and quinazoline derivatives with corticotropin releasing factor (CRF) antagonistic effect.
AU2931099A (en) * 1998-03-06 1999-09-20 Janssen Pharmaceutica N.V. Crf antagonistic pyrazolo(4,3-b)pyridines
IL148905A0 (en) * 1999-09-30 2002-09-12 Neurogen Corp Pfizer Inc Certain alkylene diamine-substituted pyrazolo{1,5,-a}-1,5-pyrimidines and pyrazolo{1,5,-a}-1,3,5-triazines
CZ20021086A3 (en) 1999-09-30 2002-10-16 Neurogen Corporation Alkylenediamine substituted heterocycles
US20010031474A1 (en) * 2000-01-28 2001-10-18 Neurogen Corporation Chimeric neuropeptide Y receptors
US20050033048A1 (en) * 2000-12-12 2005-02-10 Rajagopal Bakthavatchalam Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines
CA2403307A1 (en) 2001-10-23 2003-04-23 Neurogen Corporation Substituted 2-cyclohexyl-4-phenyl-1h-imidazole derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003510A1 (en) * 1996-07-24 1998-01-29 Du Pont Pharmaceuticals Company Azolo triazines and pyrimidines
WO1999038868A1 (en) * 1998-01-28 1999-08-05 Du Pont Pharmaceuticals Company Azolo triazines and pyrimidines
WO1999040091A1 (en) * 1998-02-06 1999-08-12 Amgen Inc. Bicyclic pyridine and pyrimidine derivatives as neuropeptide y receptor antagonists

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8835430B2 (en) 2002-02-01 2014-09-16 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US9018204B1 (en) 2002-02-01 2015-04-28 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US9346765B2 (en) 2002-02-01 2016-05-24 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US9416112B2 (en) 2002-02-01 2016-08-16 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US9913842B2 (en) 2002-02-01 2018-03-13 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US9266912B2 (en) 2005-01-19 2016-02-23 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses

Also Published As

Publication number Publication date
EP1224187B1 (en) 2006-02-22
EA200200424A1 (en) 2002-12-26
US6506762B1 (en) 2003-01-14
CZ20021086A3 (en) 2002-10-16
BG106508A (en) 2003-02-28
ZA200202518B (en) 2003-08-27
US20040229870A1 (en) 2004-11-18
PL354784A1 (en) 2004-02-23
ATE318267T1 (en) 2006-03-15
US6696445B2 (en) 2004-02-24
US7074929B2 (en) 2006-07-11
IL148903A0 (en) 2002-09-12
NO20021358L (en) 2002-05-27
US20030158197A1 (en) 2003-08-21
CA2379640C (en) 2006-11-28
DE60026155T2 (en) 2006-08-10
KR20020043223A (en) 2002-06-08
HUP0202636A3 (en) 2004-06-28
NO20021358D0 (en) 2002-03-19
ES2258476T3 (en) 2006-09-01
DE60026155D1 (en) 2006-04-27
NZ517575A (en) 2004-04-30
JP2008007515A (en) 2008-01-17
AU7738000A (en) 2001-04-30
CA2379640A1 (en) 2001-04-05
OA12050A (en) 2006-05-02
EP1224187A2 (en) 2002-07-24
JP2003510327A (en) 2003-03-18
WO2001023389A2 (en) 2001-04-05
CN1377356A (en) 2002-10-30
HUP0202636A2 (en) 2002-12-28

Similar Documents

Publication Publication Date Title
WO2001023389A3 (en) Certain alkylene diamine-substituted heterocycles
MXPA02001764A (en) Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists.
WO2001071022A3 (en) Lpa receptor agonists and antagonists and methods of use
WO2002085925A3 (en) Melanocortin receptor ligands
DE60210944D1 (en) N-SUBSTITUTED HETEROCYCLIC NONARYL-NMDA / NR2B ANTAGONISTS
CA2293621A1 (en) 4-aminopyrrole(3,2-d) pyrimidines as neuropeptide y receptor antagonists
MXPA04000707A (en) Substituted urea neuropeptide y y5 receptor antagonists.
CA2319275A1 (en) Bicyclic pyridine and pyrimidine derivatives as neuropeptide y receptor antagonists
WO2001014376A8 (en) Novel spiro compounds
WO2003042173A8 (en) Nk1 antagonists
WO2002102978A3 (en) Human growth hormone antagonists
DE60327375D1 (en) ARYLINDENOPYRIDINE AND ARYLINDENOPYRIMIDINE COMPOUNDS AND THEIR USE AS ADENOSINE A2A RECEPTOR ANTAGONISTS
WO2002014275A3 (en) Heterocyclic sulfonamide derivatives and their use for potentiating glutamate receptor function
WO2002014294A3 (en) Heterocyclic sulfonamide derivatives and their use for potentiating glutamate receptor function
EP1028113A4 (en) Fused benzene heterocycle derivatives and utilization thereof
DE69812010D1 (en) 4-aminopyrrole (3,2-d) pyrimidines as antagonists of the neuropeptide Y receptor
AU2251801A (en) Piperidine derivatives and their use as serotonin receptor antagonists
WO2001007431A3 (en) Benzothiophene derivatives
ATE383343T1 (en) IMIDAZOLE DERIVATIVES USABLE AS HISTAMINE H3 RECEPTOR LIGANDS
DK0854146T3 (en) Substituted 4- (6-fluoro- [1H] -indol-3-yl) -1,2,3,6-tetrahydropyridine for the treatment of CNS disorders
WO2002032932A3 (en) Urotensin-ii agonists and antagonists
WO2003004464A3 (en) Heterocyclic amide derivatives and the use thereof as pesticides
EP1172106A3 (en) Use of fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles as substance P receptor antagonists
EP1582519A3 (en) Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2379640

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 517575

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1200200214

Country of ref document: VN

ENP Entry into the national phase

Ref document number: 2000 106508

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 77380/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 148903

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PV2002-1086

Country of ref document: CZ

Ref document number: PA/a/2002/003326

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020027004150

Country of ref document: KR

Ref document number: P-237/02

Country of ref document: YU

ENP Entry into the national phase

Ref document number: 2001 526541

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 008137048

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2000967133

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200200424

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 1020027004150

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000967133

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2002-1086

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 517575

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 517575

Country of ref document: NZ

WWR Wipo information: refused in national office

Ref document number: 1020027004150

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 2000967133

Country of ref document: EP